Best Earnings Power Value Drug Manufacturers - Specialty & Generic Stocks 2026
Top Drug Manufacturers - Specialty & Generic stocks by Earnings Power Value (EPV) upside in 2026. Greenwald-framework normalized earnings valuation updated daily from SEC filings.
1 of the 52 companies CirclFi can value in Drug Manufacturers - Specialty & Generic trades below its 13-model median fair value as of 2026-08-27 — 1.9% of the group. SIGA Technologies, Inc. (SIGA) leads at +134.6% against the median of its active models.
This screen returns 1 name rather than the usual ten. CirclFi does not pad a directional list with stocks pointing the other way: only companies that actually clear the threshold appear, so a thin sector produces a short list.
Which Drug Manufacturers - Specialty & Generic Stocks Rank Highest by EPV Upside?
1 qualifying of 52 drug manufacturers - specialty & generic equities valued.
| # | Ticker | Company | Signal | QOC | Price | EPV Upside |
|---|---|---|---|---|---|---|
| 1 | SIGA | SIGA Technologies, Inc. | 8.4 | $3.06 | +134.6% |
You’re seeing every qualifying stock on this screen.
Access the complete dataset with 13 institutional-grade models.
How CirclFi Ranks Drug Manufacturers - Specialty & Generic Stocks
CirclFi publishes a valuation page for all 5,877 US equities it covers and can state a 13-model median fair value for the 3,801 with enough filing history for at least two models to run, 52 of them in Drug Manufacturers - Specialty & Generic — reading SEC EDGAR filings, FRED macro data, and GDELT sentiment.
For Drug Manufacturers - Specialty & Generic stocks, CirclFi adjusts sector-relative benchmarks — comparing margins, capital intensity, and growth rates against Drug Manufacturers - Specialty & Generic industry medians.
Ranking band: stocks whose implied upside exceeds +300% are excluded from this ranking. Beyond that level a currency or share-count artifact in the source filing is a more likely explanation than a genuine mispricing in a listed US equity, so CirclFi does not let those values define a ranking. Each stock's full computed range is still shown on its own page. Read the methodology →
Profitability Matrix
ROIC, Gross Margin expansion, and FCF Yield analysis.
Growth Vector
Revenue compounding vs. sector benchmarks.
Stability Index
Altman Z-Score, debt resilience, and earnings variance.
What Should You Know About This Drug Manufacturers - Specialty & Generic Screen?
What are the best earnings power value drug manufacturers - specialty & generic stocks in 2026?
CirclFi identifies the best earnings power value drug manufacturers - specialty & generic stocks 2026 using 13 institutional-grade valuation models including Bayesian DCF (10,000 Monte Carlo simulations), EPV (Greenwald framework), and EROIC Spread (McKinsey). Rankings update daily from SEC EDGAR filings. The current top-ranked stock is SIGA (SIGA Technologies, Inc.).
How does CirclFi rank Drug Manufacturers - Specialty & Generic stocks?
Stocks are ranked by EPV Upside derived from CirclFi's proprietary models. Each model independently processes SEC EDGAR financial data (700+ XBRL tags), FRED macroeconomic indicators, and GDELT news sentiment to produce confidence-weighted fair value estimates. The ranking methodology combines multiple valuation approaches — intrinsic, relative, scenario, and ensemble — for maximum robustness.
How often is the best earnings power value drug manufacturers - specialty & generic stocks 2026 list updated?
This list is recalculated daily after US market close. Every stock is re-valued through all 13 models using the latest SEC EDGAR filings, market prices, and FRED macroeconomic data. Rankings can change daily as new financial data becomes available or market prices shift relative to fair value estimates.
What is the Quality of Company (QOC) score?
The QOC score is a 0-10 composite rating derived from 32 fundamental signals across four pillars: profitability (ROE, ROIC, margins), growth (revenue CAGR, earnings acceleration), stability (earnings volatility, debt coverage), and capital efficiency (asset turnover, free cash flow yield). Higher scores indicate stronger fundamentals. Scores above 7 represent top-tier companies.
How does this list compare to other stock screeners?
Unlike simple screeners that filter by P/E or dividend yield, CirclFi runs 13 independent institutional-grade valuation models on every stock — including Bayesian DCF with Monte Carlo simulation, Greenwald EPV, and McKinsey economic profit frameworks. Each company is scored on 32 fundamental signals drawn from 700+ SEC EDGAR XBRL tags, then re-valued after every US market close. Most retail screeners use one or two metrics; this screen ranks 52 Drug Manufacturers - Specialty & Generic companies on the median of all 13.
Buy with Gumroad